Log in for full access to this activity, if you are registered.

Registration Options

Activity Dates: 06/12/2014 - 04/30/2017

This course is closed. Please look for other available products in CPNP University.

Target Audience

This course is designed for pharmacists, nurse practitioners or other healthcare professionals involved in the comprehensive medication management of psychiatric and/or neurological patients.

Session Summary

Attention Deficit Hyperactivity Disorder can persist beyond childhood to impact the entire lifespan. Prevalence estimates vary by method of study, but approximately 9 % of children meet criteria for the condition, and the condition persists into adulthood in about half of cases. Clinical trials have demonstrated the efficacy of pharmacotherapies for symptoms of attention and behavior control, with less data on broader life impact. Organizational challenges often require separate support in addition to pharmacotherapy.  Initial studies demonstrate efficacy of behavioral therapies for ADHD, and cognitive training and neurofeedback approaches are being explored. Personalized recommendations should be tailored to the potential risks and benefits, accounting for presence of comorbid mental health conditions, contraindications to agents, and evidence from studies in populations that are generalizable to the patient’s circumstances.

Course Requirements

You will proceed through the following steps to satisfactorily complete this course:

  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date. (login first)
  • Complete the evaluation at the end of the activity. (login first)
  • If necessary, complete the post-test retest no later than the closing activity date. (login first)
  • Receive a passing grade (70%).
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor. (login first)

This course is provided online at cpnp.org and consists of the speaker audio and slides. A PDF file of the slides is also provided and access is available to participants indefinitely although ACPE credit is available only through the course expiration date.

Participants in this course must complete an examination and achieve a score of 70% or greater. Successful completion of the course also requires the completion of a course evaluation. ACPE statements of credit can be retrieved by participants online at cpnp.org immediately upon successful completion of the course.

Faculty Information and Disclosures

Learning Objectives


  1. Discuss the epidemiology of ADHD in children and adults.

  2. Evaluate evidence-based medication treatment in children and adults and discuss emerging data for adjunctive behavioral therapy.

  3. Identify clinical signs and symptoms that present among patients with ADHD that limit the safety of pharmacotherapy including misuse/abuse of medications, dependence/addiction and comorbid conditions.

  4. Discuss the current understanding of functional outcomes and generalizability of pharmacotherapy efficacy to special populations.

  5. Review best practices in monitoring efficacy and tolerability, and personalizing pharmacotherapy among children and adults with ADHD.


Continuing Education Credit and Disclosures

Activity Dates: 06/12/2014 - 04/30/2017
ACPE Contact Hours: 1.0
ACPE Number: 0284-0000-14-024-H01-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This course provides 1.0 contact hours (0.10CEUs) of knowledge-based continuing education credit. The ACPE universal program number assigned to this course is 0284-0000-14-024-H01-P (1.0 contact hours).